Abstract
Many decisions in drug development and medical practice are based on measuring blood concentrations of endogenous and exogenous molecules. Yet most biochemical and pharmacological events take place in the tissues. Also, most drugs with few notable exceptions exert their effects not within the bloodstream, but in defined target tissues into which drugs have to distribute from the central compartment. Assessing tissue drug chemistry has, thus, for long been viewed as a more rational way to provide clinically meaningful data rather than gaining information from blood samples. More specifically, it is often the extracellular (interstitial) tissue space that is most closely related to the site of action (biophase) of the drug. Currently microdialysis (μD) is the only tool available that explicitly provides data on the extracellular space. Although μD as a preclinical and clinical tool has been available for two decades, there is still uncertainty about the use of μD in drug research and development, both from a methodological and a regulatory point of view. In an attempt to reduce this uncertainty and to provide an overview of the principles and applications of μD in preclinical and clinical settings, an AAPS-FDA workshop took place in November 2005 in Nashville, TN, USA. Stakeholders from academia, industry and regulatory agencies presented their views on μD as a tool in drug research and development.
References
U. Ungerstedt and C. Pycock. Functional correlates of dopamine neurotransmission. Bull. Schweiz. Akad. Med. Wiss. 30:44–55 (1974).
E. C. M. De Lange, A. G. De Boer, and D. D. Breimer. Methodological issues in microdialysis sampling for pharmacokinetic studies. Eds. R. Sawchuk and W. F. Elmquist. Adv. Drug Deliv. Rev. 45:125–148 ( 2000).
W. F. Elmquist and R. J. Sawchuk. Application of microdialysis in pharmacokinetic studies. Pharm. Res. 14:267–288 (1997).
C. S. Chaurasia. In vivo microdialysis sampling: theory and applications. Biomed. Chromatogr. 13:317–332 (1999).
E. C. M. De Lange, and M. Danhof: Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain. Clin. Pharmacokinet. 41:691–703, 2002.
M. I. Davies, J. D. Cooper, S. S. Desmond, C. E. Lunte, and S. M. Lunte. Analytical considerations for microdialysis sampling. Adv. Drug Deliv. Rev. 45:169–88 (2000).
E. C. M. De Lange, M. Danhof, A. G. De Boer, and D. D. Breimer. Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on blood–brain barrier transport of drugs. Brain Res. Rev. 25:27–49 (1997).
U. Ungerstedt. Microdialysis—principles and applications for studies in animals and man. J. Intern. Med. 230:365–373 (1991).
E. C. M. De Lange, A. H. de Bock, A. G. de Boer Schinkel, and D. D. Breimer. BBB transport and P-glycoprotein functionality using MDR1A (−/−) and wild-type mice. Total brain versus microdialysis concentration profiles of rhodamine-123. Pharm. Res. 15:1657–1665 (1998).
P. M. Bungay and R. L. Dedrick, E. Fox, and F. M. Balis. Probe calibration in transient microdialysis in vivo. Pharm. Res. 18:361–366 (2001).
A. D. Smith and J. B. Justice Jr. The effect of inhibition of synthesis, release, metabolism and uptake on the microdialysis extraction fraction of dopamine. J. Neurosci. Methods 54:75–82 (1994).
E. C. M. De Lange, P. G. M. Ravenstijn, D. Groenendaal, and T. S. van Steeg. Towards the prediction of CNS drug effect profiles in physiological and pathological conditions using microdialysis and mechanism-based pharmacokinetic-pharmacodynamic modeling. AAPS J. 7:E532–543, (2005).
P. Ederoth, K. Tunblad, R. Bouw, J. C. F. Lundberg, U. Ungerstedt, C. H. Nordström, and M. Hammarlund-Udenaes. Blood–brain barrier transport of morphine in patients with severe brain trauma. Brit. J. Clin. Pharmacol. 57:427–435 (2004).
L. B. Stolle, M. Arpi, P. Holmberg-Jorgensen, P. Riegels-Nielsen, and J. Keller. Application of microdialysis to cancellous bone tissue for measurement of gentamicin levels. J. Antimicrob. Chemother. 54:263–265 (2004).
T. Zhu, B. W. Cheung, L. L. Cartier, G. S. Giebink, and R. J. Sawchuk. Simultaneous intravenous and intramiddle-ear dosing to determine cefditoren influx and efflux clearances in middle ear fluid in freely moving chinchillas. J. Pharm. Sci. 92:1947–1956 (2003).
S. R. Skilling, D. H. Smullin, A. J. Beitz, and A. A. Larson. Extracellular amino acid concentrations in the dorsal spinal cord of freely moving rats following veratridine and nociceptive stimulation. J. Neurochem. 51:127–132, (1988).
B. S. Anand, H. Atluri, and A. K. Mitra. Validation of an ocular microdialysis technique in rabbits with permanently implanted vitreous probes: systemic and intravitreal pharmacokinetics of fluorescein. Int. J. Pharm. 28:79–88 (2004).
M. Qian, W. West, J. T. Wu, B. Lu, and D. D. Christ. Development of a dog microdialysis model for determining synovial fluid pharmacokinetics of anti-arthritis compounds exemplified by methotrexate. Pharm. Res. 20:605–10 (2003).
E. Solligård, I. S..Juel, K. Bakkelund, P.Jynge, K. E. Tvedt H. Johnsen, P. Aadahl, and J. E. Grønbech. Gut luminal microdialysis of glycerol as a marker of intestinal ischemic injury and recovery. Crit. Care Med. 33:2278–2285 (2005).
J. L. Krup and C. M. Bernards. Pharmacokinetics of intrathecal oligodeoxynucleotides. Anesthesiology. 100:315–322 (2004).
Y. Wang and R. J. Sawchuk. Zidovudine transport in the rabbit brain during intravenous and intracerebroventricular infusion. J. Pharm. Sci. 84:871–876 (1995).
J. Riese, S. Boecker, W. Hohenberger, P. Klein, and W. Haupt. Microdialysis: a new technique to monitor perioperative human peritoneal mediator production. Surg. Infect. 4:11–5 (2003).
M. Brunner and M. Muller. Microdialysis: an in vivo approach for measuring drug delivery in oncology. Eur. J. Clin. Pharmacol. 58: 227-234 (2002).
A. Galvan, Y. Smith, and T. Wichmann. Continuous monitoring of intracerebral glutamate levels in awake monkeys using microdialysis and enzyme fluorometric detection. J.Neurosci. Methods. 126:175–85 (2003).
P. F. Morrison, P. M. Bungay, J. K. Hsiao, I. N. Mefford,K. H. Dykstra, and R. L. Dedrick. Quantitative microdialysis. In: T. E. Robinson, J. B. Justice, Jr. (eds.), Microdialysis in the Neurosciences. Elsevier, N.Y., 1996, pp. 47–80.
K. C. Chen, M. Höistad, J. Kehr, J., K. Fuxe, and C. Nicholson. Theory relating in vitro and in vivo microdialysis of one or two probes. J. Neurochem. 81:108–121 (2002).
P. M. Bungay, P. F. Morrison, R. L. Dedrick, V. I. Chefer, A. Zapata. Principles of Quantitative Microdialysis. In B. H. C. Westerink, T. I. F. H. Cremers (eds.) Handbook of Microdialysis, Vol. 16: Methods, Applications and Perspectives. Elsevier, N.Y. (in press).
P. Lönnroth, P A. Jansson, and U. Smith. A microdialysis method allowing characterization of intercellular water space in humans. Am. J. Physiol. 253(2 pt 1):E228–E231(1987).
R. J. Olson and J. B. Justice, Jr. Quantitative microdialysis under transient conditions. Anal. Chem. 65:1017–1022 (1993).
Y. S. L. Wang, and R. J. Sawchuk. Microdialysis calibration using retrodialysis and zero-net flux: application to a study of the distribution of zidovudine to rabbit cerebrospinal fluid and thalamus. Pharm. Res. 10:1411–1419 (1993).
M. R. Bouw, M. Hammarlund-Udenaes. Methodological aspects of the use of a calibrator in in vivo microdialysis—further development of the retrodialysis method. Pharm. Res. 15:1673–1679 (1998).
L. Strindberg and P. Lönnroth. Validation of an endogenous reference technique for the calibration of microdialysis catheters. Scand. J. Clin. Lab. Invest. 60:205–211 (2000).
H. Yang, J. L. Peters, and A. C. Michael. Coupled effects of mass transfer and uptake kinetics on in vivo microdialysis of dopamine. J. Neurochem. 71:684–692 (1998).
P. M. Bungay, P. Newton-Vinson, W. Isele, P. A. Garris, and J. B. Justice, Jr. Microdialysis of dopamine interpreted with quantitative model incorporating probe implantation trauma. J. Neurochem. 86:932–946 (2003).
K. C. Chen. Effects of tissue trauma on the characteristics of microdialysis zero-net-flux method sampling neurotransmitters. J. Theor. Biol. 238:863–881 (2006).
K. H. Dystra, J. K. Hsiao,P. F. Morrison,P. M. Bungay, I. N. Mefford, M. M. Scully, and R. L. Dedrick. Quantitative examination of tissue concentration profiles associated with microdialysis. J. Neurochem. 58:931–940 (1992).
M. Höistad, K. C. Chen, C. Nicholson, K. Fuxe, and J. Kehr. Quantitative dual-probe microdialysis: evaluation of [3H]mannitol diffusion in agar and rat striatum. J. Neurochem. 81:80–93 (2002).
P. Lönnroth and L. Strindberg. Validation of the ‘internal reference technique’ for calibrating microdialysis catheters in situ. Acta. Physiol. Scand. 153:375–80 (1995).
M. Müller. Science, medicine and the future: microdialysis. BMJ 324:588–591 (2002).
M. Müller. Microdialysis in clinical drug delivery studies. Adv. Drug. Deliv. Rev. 45:255–269 (2000).
C. Kennergren, V. Mantovani, L. Strindberg, E. Berglin, A. Hamberger, P. Lönnroth. Myocardial interstitial glucose and lactate before, during, and after cardioplegic heart arrest. Am. J. Physiol., Endocrinol. Metabol. 284:E788–94 (2003).
B. M. Bellander, E. Cantais E, P. Enblad et al. Consensus meeting on microdialysis in neurointensive care. Intensive Care Med. 30(12):2166–2169 (2004).
C. M. Tolias and M. R. Bullock. Critical Appraisal of Neuroprotection T1 Injury: What Have We Learned? NeuroRx 1:71–79 (2004).
M. Müller, A. dela Pena, and H. Derendorf. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue. Antimicrob. Agents Chemother. 48:1441–53 (2004).
M. Brunner, H. Derendorf, and M. Müller. Microdialysis for in vivo pharmacokinetic/pharmacodynamic characterization of anti-infective drugs. Curr. Opin. Pharmacol. 5:495–499 (2005).
M. Brunner and M. Müller. Microdialysis: an in vivo approach for measuring drug delivery in oncology. Eur. J. Clin. Pharmacol. 58:227–234 (2002)
V. P. Shah, G. L. Flynn, A Yacobi, H. I. Maibach, C. Bon, N. M. Fleischer, T. J. Franz, S. A. Kaplan, J. Kawamoto, L. J. Lesko, J. P. Marty, L. K. Pershing, H. Schaefer, J. A. Sequeira, S. P. Shrivastava, and W. J. Wilkin. Bioequivalence of topical dermatological dosage forms—methods of evaluation of bioequivalence. Pharm. Res. 15: 167–171 (1998).
M. Kreilgaard, M. J. Kemme, J. Burggraff, R. C. Schoemaker, and A. F. Cohen. Influence of a microemulsion vehicle on cutaneous bioequivalence of a lipophilic model drug assessed by microdialysis and pharmacodynamics. Pharm. Res. 18:593–599, (2001).
L. Groth L, P. García Ortiz, and E. Benfeldt. Microdialysis methodology for sampling in the skin. In: J Serup, GBE Jemec, and G Grove (eds.), Handbook of Non-Invasive Methods and the Skin. CRC, Boca Raton: 2006, pp. 443–454.
E. Benfeldt, J. Serup, and T. Menne. Effect of barrier perturbation on cutaneous salicylic acid penetration in human skin: in vivo pharmacokinetics using microdialysis and non-invasive quantification of barrier function. Br. J. Dermatol. 140:739–748 (1999).
S. McDonald and C. Lunte. Determination of the dermal penetration of esterom components using microdialysis sampling. Pharm. Res. 20:1827–1834 (2003).
E. Benfeldt, S. Honoré Hansen, A. Vølund, T. Menné, and V. P. Shah. Bioequivalence of topical formulations in humans: evaluation by dermal microdialysis sampling and the dermato-pharmacokinetic method. J. Invest. Dermatol. July 27(2006) (in press).
P. Lönnroth. Microdialysis in adipose tissue and skeletal muscle. Horm. Metab. Res. 29:344–346 (1997).
F. Magkos and L. S. Sidossis. Methodological approaches to the study of metabolism across individual tissues in man. Curr. Opin. Clin. Nutr. Metab. Care 8:501–510 (2005).
V. Qvisth, E. Hagström-Toft, S. Enoksson, R. S. Sherwin, S Sjöberg, and J. Bolinder. Combined hyperinsulinemia, but not hyperinsulinemia alone, suppress human skeletal muscle lipolytic activity in vivo. J. Clin. Endocrinol. Metab. 89:4693–4700 (2004).
J. Bolinder, U. Ungerstedt, and P. Arner. Long-term continuous glucose monitoring with microdialysis in ambulatory insulin-dependent diabetic patients. Lancet 342:1080–1085 (1993).
A. Maran, C Crepaldi, A. Tiengo, G. Grassi, E. Vitali, G. Pagano, S. Bistoni, G. Calabrese, F. saneusanio, F. Leonetti, M. Ribaudo, U. Di Mario, G. Anuzzi, S. Genovese, G. Riccardi, M. previti, D. Cucinotta, F. Giorgino, A. Bellomo, R. Giorgino, A. Poscia, and M Varalli. Continuous subcutaneous glucose monitoring in diabetic patients: a multicenter analysis. Diabetes Care 25: 347–352 (2002).
D. C. Klonoff. Continuous glucose monitoring: roadmap for 21st century diabetes therapy. Diabetes Care 28:1231–1239 (2005).
D. L. Kellogg Jr., Y. Liu, P. E. Pergola, and L. J. Roman. In Vivo measurement of nitric oxide concentrations in humans. FASEB J. 13:A104 (1999).
(CMA Cerebral Tissue Monitoring System, http://www.microdialysis.se/USA/PDF/510(k)%20Summary.pdf (accessed 10/23/06)
Physicians’ Desk Reference (2006) Zonegran® clinical pharmacology FDA-approved label. http://www.thomsonhc.com/pdrel/librarian/PFDefaultActionId/pdrcommon.IndexSearchTranslator), (accessed 10/23/06)
Catalyst pharmaceuticals partners files investigational new drug application for CPP-109 to treat cocaine addiction (2005) http://www.bnl.gov/CTN/GVG/CPP.asp), (accessed 10/23/06)
Anti-infective Drug Advisory Committee Meeting (1998). Guidance documents on developing antimicrobial drugs: general considerations and individual indications. Gaithersburg, MD, July 31 http://www.fda.gov.lilac.une.edu/ohrms/dockets/ac/cder98t.htm#Anti-InfectiveDrugs
EMEA (2006). 4.1.2. In vivo studies in: guideline on the non-clinical investigation of the dependence potential of medicinal products. European Medicines Agency, Evaluation of Medicines for Human Use. http://www.emea.eu.int/pdfs/human/swp/9422704en.pdf) (accessed 10/23/06)
FDA (2004). Innovation or stagnation? Challenge and opportunity on the Critical Path to new medical products. US Department of Health and Human Services, Food and Drug Administration.
Author information
Authors and Affiliations
Corresponding author
Additional information
The views expressed in this paper are those of the authors and do not necessarily reflect the opinions of their companies/institutions or the official policy of the FDA. No official support or endorsement by the FDA is intended or should be inferred. The contents of this report were presented by the authors at the Microdialysis Workshop, Nashville, TN, Nov 4–5, 2005 organized by American Association of Pharmaceutical Scientists and Co-Sponsored with the US Food and Drug Administration.
Rights and permissions
About this article
Cite this article
Chaurasia, C.S., Müller, M., Bashaw, E.D. et al. AAPS-FDA Workshop White Paper: Microdialysis Principles, Application and Regulatory Perspectives. Pharm Res 24, 1014–1025 (2007). https://doi.org/10.1007/s11095-006-9206-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11095-006-9206-z